Moderna (MRNA) Stock Buyback History
TTM buyback yield N/A.
MRNA
TTM buyback yield
N/A
Shareholder yield (TTM)
N/A
5Y share count change
2.0%
TTM buyback spend
N/A
SBC coverage (TTM)
0.00x
YoY change in spend
N/A
5Y CAGR of spend
N/A
Peak year (2022)
$3.33B
Cumulative spend
$5.35B
TTM metrics calculated from the four most recent reported quarters, ending (reported ).
Key takeaways
- Diluted share count is up 2.0% over the last ~5 fiscal years — equity issuance and stock-based compensation are outpacing repurchases.
Buyback context per fiscal year
Annual repurchases alongside stock-based compensation, diluted share count and the year-over-year change — useful for SBC-coverage and dilution-offset reading at a glance.
| Year | Buybacks | SBC | Net | Shares (dil.) | YoY shares | Buyback yield |
|---|---|---|---|---|---|---|
| 2025 | $0.00 | $483.00M | −$483.00M | 0.39B | 1.3% | — |
| 2024 | $0.00 | $429.00M | −$429.00M | 0.38B | 0.5% | — |
| 2023 | $1.15B | $305.00M | $848.00M | 0.38B | -8.2% | 3.04% |
| 2022 | $3.33B | $226.00M | $3.10B | 0.42B | -3.5% | 4.81% |
| 2021 | $857.00M | $142.00M | $715.00M | 0.43B | 13.0% | 0.83% |
| 2020 | $0.00 | $93.00M | −$93.00M | 0.38B | 15.3% | — |
| 2019 | $2.89M | $81.12M | −$78.23M | 0.33B | 0.6% | 0.04% |
| 2018 | $8.18M | $72.56M | −$64.38M | 0.33B | -12.6% | 0.16% |
| 2017 | $0.00 | $40.05M | −$40.05M | 0.38B | 486.6% | — |
| 2016 | $0.00 | $39.36M | −$39.36M | 0.06B | — | — |
Cash buyback spend (USD) — annual & quarterly history
Trailing-twelve-month and per-period cash repurchases for Moderna (MRNA) from the consolidated cash flow statement (line: common stock repurchased), in USD as filed.
Cash buyback spend over time for Moderna (MRNA)
Per-period cash repurchases
Cash buyback spend annual + quarterly history for Moderna (MRNA)
| Fiscal year | Period ended | Reported | Buyback Spend | YoY | YoY change |
|---|---|---|---|---|---|
| 2025 | $0 | — | $0 | ||
| 2024 | $0 | -100.0% | -$1.15B | ||
| 2023 | $1.15B | -65.4% | -$2.18B | ||
| 2022 | $3.33B | +288.4% | +$2.47B | ||
| 2021 | $857.00M | — | +$857.00M | ||
| 2020 | $0 | -100.0% | -$2.89M | ||
| 2019 | $2.89M | -64.7% | -$5.29M | ||
| 2018 | $8.18M | — | +$8.18M | ||
| 2017 | $0 | — | $0 | ||
| 2016 | $0 | — | — |
In 2025, Moderna (MRNA) buyback spend totalled $0.
Moderna buyback spend peaked at $3.33B in 2022; the latest annual figure is $0 in 2025 (100.0% below peak).
The highest annual buyback spend of $3.33B was reported in 2022. The lowest in the available history was $0 in 2016.
Within Healthcare, Moderna (MRNA) ranks 8th among 8 peers we track. The peer median for buyback spend is $2.75B.
Moderna Buyback Spend 2025: $0
Moderna buyback spend in 2025 was $0.
Moderna Buyback Spend 2024: $0
Moderna buyback spend in 2024 was $0, plunged 100.0% below 2023.
Moderna Buyback Spend 2023: $1.15B
Moderna buyback spend in 2023 was $1.15B, plunged 65.4% below 2022.
Moderna Buyback Spend 2022: $3.33B
Moderna buyback spend in 2022 was $3.33B, surged 288.4% from 2021. This figure represents the highest annual value in the available history.
Moderna Buyback Spend 2021: $857.00M
Moderna buyback spend in 2021 was $857.00M.
See more financial history for Moderna (MRNA).
Sector peers by buyback spend
Companies in the same sector as Moderna, ranked by their latest buyback spend.
| Company | Buyback Spend | Sector |
|---|---|---|
| Johnson & Johnson (JNJ) | $5.95B | Healthcare |
| UnitedHealth Group (UNH) | $5.54B | Healthcare |
| Merck & Co. (MRK) | $5.08B | Healthcare |
| Eli Lilly (LLY) | $4.11B | Healthcare |
| Novo Nordisk (NVO) | $1.39B | Healthcare |
| AbbVie (ABBV) | $980.00M | Healthcare |
| AstraZeneca (AZN) | $719.66M | Healthcare |
| Amgen (AMGN) | $0 | Healthcare |
Share count history
Diluted weighted-average shares drive the EPS denominator and per-share capital-return maths. A falling diluted share count means buybacks are outpacing dilution from stock-based compensation and option exercises.
Diluted vs basic shares (annual)
Year-over-year change in diluted shares
Green is fewer shares vs the prior fiscal year (net repurchase); red is growth (dilution). The earliest year shown has no prior year to compare.
Dividend & buyback yield over time
Stacked annual yields — buyback yield (TTM cash repurchases ÷ market cap) plus dividend yield from the same fiscal-year-end key-metrics period — show how total cash return per dollar of equity has evolved.
Buybacks vs stock-based compensation
Annual cash repurchases set against stock-based compensation. Coverage above 1× means buybacks fully offset the equity dilution from SBC. TTM coverage: 0.00×.
Capital allocation mix
How Moderna splits cash returned to shareholders between dividends and buybacks, plus the headroom on free cash flow that's still available for additional repurchases.
Buybacks vs dividends (share of cash returned)
Buyback capacity (TTM)
Free cash flow minus dividends paid versus actual TTM repurchases — the headroom bar shows how much of post-dividend FCF is still being deployed elsewhere.
Headroom $0.00 (TTM FCF − TTM dividends, clamped at zero).
Data & methodology
Where do buyback, dividend and compensation figures come from?
Cash buyback spend (common stock repurchased), dividends paid and stock-based compensation come from Moderna's consolidated cash flow statements — quarterly 10-Q and annual 10-K SEC filings, in USD as reported.
How are diluted shares and yields calculated?
Diluted weighted-average share counts come from the income statement (EPS denominator). Trailing twelve-month (TTM) aggregates sum the four most recent reported quarters. Buyback and dividend yields divide TTM cash flows by market capitalisation at the latest quarter-end.
How is buyback capacity defined?
Capacity compares TTM repurchases to free cash flow after dividends: operating cash flow minus capital expenditure, minus dividends paid, versus actual buybacks over the same trailing window.
Is this investment advice?
No. Figures are for informational and educational use only. Past buybacks and dividends do not predict future returns.
Frequently asked questions
Does Moderna buy back its own stock?
Yes, Moderna (MRNA) has repurchased shares in recent periods. See the history table and charts on this page for amounts and trends.
Is Moderna diluting shareholders?
Compare stock-based compensation (SBC) to buybacks in the chart above. Net effect varies by year; see annual buyback vs SBC bars and the history table.
How has Moderna's share count changed?
Diluted weighted average shares changed by about 2.0% over roughly five fiscal years (annual income statement data).
What is Moderna's buyback spend?
Latest reported buyback spend for Moderna (MRNA) is $0 (period ending March 31, 2026).
When did Moderna buyback spend hit its highest annual value?
Moderna buyback spend reached its highest annual value of $3.33B in 2022.
What was Moderna buyback spend in 2024?
Moderna (MRNA) buyback spend in 2024 was $0.
What was Moderna buyback spend in 2025?
Moderna (MRNA) buyback spend in 2025 was $0.
Explore more
MRNA Overview
Company profile, financial tools, and key metrics
MRNA Revenue Counter
Earns $70.55 every second. See per minute, hour, and day.
MRNA Earnings Counter
Loses −$101.28 per second. See per minute, hour, and day.
MRNA Economic Scale
Exceeds Guinea-Bissau's GDP. Compare with world economies.
MRNA What If Invested
What if you had invested $1,000? See historical returns from any date.
MRNA How It Makes Money
Discover visual breakdown of $2.23B in revenue — where it comes from and where it goes.
MRNA Stock Seasonality
Best and worst months to invest. Historical monthly returns heatmap.
MRNA Price Target Scenarios
Model bear, base, and bull cases with EPS growth and exit P/E — pre-filled from analysts and history.
MRNA Daily Price Character
Explosive · 48.2% historical win rate (green days). Streaks & record days.
MRNA Financials
Revenue, EPS, EBITDA, market cap, debt and balance sheet history with annual and quarterly data.